Posted by Michael Wonder on 08 Jan 2023
JAMP Pharma Group receives Health Canada approval for JAMP Sitagliptin, a new generic alternative for the treatment of type 2 diabetes
6 January 2022 - The JAMP Pharma Group is pleased to announce the Health Canada approval of JAMP Sitagliptin, a generic alternative to the reference product Januvia from Merck Canada.
JAMP Sitagliptin, which will be available soon, is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contra-indications or intolerance.
